Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.
The absence of functional von Hippel-Lindau (VHL) tumor suppressor gene leads to the development of neoplasias characteristic of VHL disease, including renal cell carcinoma (RCC). Here, we compared the sensitivity of RCC cells lacking VHL gene function with that of RCC cells expressing the wild-type VHL gene (wtVHL) after exposure to various stresses. While the response to most treatments was not affected by the VHL gene status, glucose deprivation was found to be much more cytotoxic for RCC cells lacking VHL gene function than for wtVHL-expressing cells. The heightened sensitivity of VHL-deficient cells was not attributed to dissimilar energy requirements or to differences in glucose uptake, but more likely reflects a lesser ability of VHL-deficient cells to handle abnormally processed proteins arising from impaired glycosylation. In support of this hypothesis, other treatments which act through different mechanisms to interfere with protein processing (i.e., tunicamycin, brefeldin A, and azetidine) were also found to be much more toxic for VHL-deficient cells. Furthermore, ubiquitination of cellular proteins was elevated in VHL-deficient cells, particularly after glucose deprivation, supporting a role for the VHL gene in ubiquitin-mediated proteolysis. Accordingly, the rate of elimination of abnormal proteins was lower in cells lacking a functional VHL gene than in wtVHL-expressing cells. Thus, pVHL appears to participate in the elimination of misprocessed proteins, such as those arising in the cell due to the unavailability of glucose or to other stresses.
Gorospe
M
M
Laboratory of Biological Chemistry, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA. myriam-gorospe@nih.gov
Egan
J M
JM
Zbar
B
B
Lerman
M
M
Geil
L
L
Kuzmin
I
I
Holbrook
N J
NJ
D017209:Apoptosis; D001483:Base Sequence; D002292:Carcinoma, Renal Cell / Q000209:etiology / Q000235:genetics* / Q000378:metabolism*; D004734:Energy Metabolism; D016147:Genes, Tumor Suppressor; D019254:Genes, bcl-2; D005947:Glucose / Q000378:metabolism; D006031:Glycosylation; D006801:Humans; D007680:Kidney Neoplasms / Q000209:etiology / Q000235:genetics* / Q000378:metabolism*; D008025:Ligases; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D011499:Protein Processing, Post-Translational; D011506:Proteins / Q000235:genetics* / Q000378:metabolism*; D012334:RNA, Neoplasm / Q000235:genetics; D012337:RNA, Ribosomal, 18S / Q000235:genetics; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D014452:Ubiquitins / Q000378:metabolism; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D006623:von Hippel-Lindau Disease / Q000150:complications / Q000235:genetics* / Q000378:metabolism*
D009363:Neoplasm Proteins; D011506:Proteins; D012334:RNA, Neoplasm; D012337:RNA, Ribosomal, 18S; D025521:Tumor Suppressor Proteins; D014452:Ubiquitins; D044767:Ubiquitin-Protein Ligases; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D008025:Ligases; C497446:VHL protein, human; D005947:Glucose